Twenty patients with squamous cell carcinoma of the head and neck (SCC H/N) were treated with Adriamycin (doxorubicin) at a dosage of 60 mg/m\* at 3-week intervals. No patient had received surgery, radiation, or chemotherapy before treatment with Adriamycin. Responses were observed in 44% of 18 eval
Phase II study of induction and adjuvant chemotherapy for squamous cell carcinoma of the head and neck : A long term analysis for the Illinois Cancer Center
โ Scribed by Ilias Athanasiadis; Samuel Taylor IV; Everett E. Vokes; Harold J. Pelzer; Alfred Rademaker; Bharat B. Mittal; Natalia Ganzenko; Richard Blough; Eric P. Lester; Merrill S. Kies
- Publisher
- John Wiley and Sons
- Year
- 1997
- Tongue
- English
- Weight
- 108 KB
- Volume
- 79
- Category
- Article
- ISSN
- 0008-543X
No coin nor oath required. For personal study only.
โฆ Synopsis
the following treatment was administered: Induction chemotherapy (cisplatin and infusional 5-
๐ SIMILAR VOLUMES
Background. There is little literature comparatively evaluating the results of postoperative radiation therapy (RT) for patients with squamous cell carcinoma (SCC) of the head and neck treated for primary versus recurrent disease. Methods. Between 1981 and 1993, 174 patients with SCC of the head an
## BACKGROUND. The combination of vinorelbine (VNR), cisplatin (CDDP), and 5-fluoro-